Drugs /

pf-07220060

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), with potential antineoplastic activity. Upon administration, CDK4 inhibitor PF-07220060 selectively inhibits CDK4, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and inhibits tumor cell proliferation. CDK4, a serine/threonine kinase, is upregulated in many tumor cell types and plays a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.

Clinical Trials

View Clinical Trials for pf-07220060

Pf-07220060 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pf-07220060, 1 is phase 1 (1 open).

CCND1 Amplification, CDK4 Amplification, and ER Expression are the most frequent biomarker inclusion criteria for pf-07220060 clinical trials.

Breast carcinoma, colorectal carcinoma, and liposarcoma are the most common diseases being investigated in pf-07220060 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pf-07220060
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pf-07220060 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cdk4 inhibitor pf-07220060, pf 07220060, pf07220060
Drug Target(s) [2]:
CDK4
NCIT ID [1]:
C175962

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.